Page 1397 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 76 Origin of Non-Hodgkin Lymphoma 1243

Jardin F, Gaulard P, Buchonnet G, et al: Follicular lymphoma without Rosebeck S, Rehman AO, Lucas PC, et al: From MALT lymphoma to the
t(14;18) and with BCL6 rearrangement: A lymphoma subtype with CBM signalosome: Three decades of discovery. Cell Cycle 10:2485, 2011.
distinct pathological, molecular and clinical characteristics. Leukemia Rosenwald A: The use of molecular profiling to predict survival after chemo-
16:2309, 2002. therapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937, 2002.
Jost PJ, Ruland J: Aberrant NF-kappaB signaling in lymphoma: Mechanisms, Rosenwald A, Wright G, Leroy K, et al: Molecular diagnosis of primary
consequences, and therapeutic implications. Blood 109:2700, 2007. mediastinal B cell lymphoma identifies a clinically favorable subgroup
Kucuk C, Jiang B, Hu X, et al: Activating mutations of STAT5B and STAT3 of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp
in lymphomas derived from gammadelta-T or NK cells. Nat Commun Med 198:851, 2003.
6:6025, 2015. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression
Leich E, Zamo A, Horn H, et al: MicroRNA profiles of t(14;18)-negative signature is a quantitative integrator of oncogenic events that predicts
follicular lymphoma support a late germinal center B-cell phenotype. survival in mantle cell lymphoma. Cancer Cell 3:185, 2003.
Blood 118:5550, 2011. Roschewski M, Staudt LM, Wilson WH: Diffuse large B-cell lymphoma-
Lenz G, Nagel I, Siebert R, et al: Aberrant immunoglobulin class switch treatment approaches in the molecular era. Nat Rev Clin Oncol
recombination and switch translocations in activated B cell-like diffuse 11(1):12–23, 2014.
large B cell lymphoma. J Exp Med 204:633, 2007. Schaffner C, Idler I, Stilgenbauer S, et al: Mantle cell lymphoma is character-
Lenz G, Wright G, Dave SS, et al: Lymphoma/Leukemia Molecular Profiling ized by inactivation of the ATM gene. Proc Natl Acad Sci USA 97:2773,
Project: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2000.
359:2313, 2008. Tam W: Mutational analysis of PRDM1 indicates a tumor-suppressor role in
Magrath I: Epidemiology: Clues to the pathogenesis of Burkitt lymphoma. diffuse large B-cell lymphomas. Blood 107:4090, 2006.
Br J Haematol 156:744, 2012. Volpe G, Vitolo U, Carbone A, et al: Molecular heterogeneity of B-lineage
McHeyzer-Williams M, Okitsu S, Wang N, et al: Molecular programming diffuse large cell lymphoma. Genes Chromosomes Cancer 16:21,
of B cell memory. Nat Rev Immunol 12:24, 2011. 1996.
Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of Wang LD, Clark MR: B-cell antigen-receptor signalling in lymphocyte
histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298, development. Immunology 110:411, 2003.
2011. Weinstock DM, Dalla-Favera R, Gascoyne RD, et al: A roadmap for
Pasqualucci L: Inactivation of the PRDM1/BLIMP1 gene in diffuse large B discovery and translation in lymphoma. Blood 125(13):2175–2177,
cell lymphoma. J Exp Med 203:311, 2006. 2015.